Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

1.00 CME
60 MINS
$0 FEE
SAVE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Immune-based Therapies in the Management of Patients With Severe COVID-19: What Do We Know?

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education


Support Statement

This activity is supported by an educational grant from Genentech, a member of the Roche Group.


Activity Description

The COVID-19 pandemic has led to an unprecedented health care crisis with widespread global morbidity and mortality. Severe COVID-19 is characterized by a hyperinflammatory state and significant pulmonary disease that can result in respiratory failure and organ damage. Immune-based treatment strategies targeting the interleukin (IL)-6 and other immunomodulatory pathways have shown promise for reducing the risk of disease progression and death in hospitalized patients with COVID-19. Recent advances have spurred unprecedented levels of ongoing clinical research, creating a substantial challenge for clinicians to stay up-to-date on the latest evidence-based care and rapidly evolving treatment guidelines. In this educational video, a multidisciplinary panel of experts will review the immunopathology underlying hyperinflammation in severe COVID-19; appraise the current evidence for immune-based therapies; and examine patient and disease characteristics that may impact response to IL-6 inhibition and other immunomodulatory therapy for severe disease. 


Target Audience

The intended audience for this activity is infectious disease specialists, pulmonologists, rheumatologists, hospitalists, critical care physicians, intensivists, and other health care professionals involved in the management of patients with COVID-19.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Summarize the immunopathology of COVID-19 infection as it relates to the stages of disease, with an emphasis on hyperinflammation in severe disease.
  • Assess the latest clinical evidence regarding the use of immune-based therapies in patients with severe COVID-19 infection.
  • Examine how features such as disease severity and prior treatment history may impact response to IL-6 inhibitors in patients with severe COVID-19 infection.

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH


Faculty

Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Ivan O. Rosas, MD
Professor and Section Chief
Pulmonary, Critical Care and Sleep Medicine
Lester and Sue Smith Chair in Lung Health
Baylor College of Medicine
Houston, TX


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material is approved for 1 year from the date of original release, October 20, 2021 to October 19, 2022.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Paul G. Auwaerter, MD, MBA, FIDSA
Ownership Interest: Johnson & Johnson

Cassandra Calabrese, DO
Speakers Bureau: Sanofi-Genzyme

Leonard H. Calabrese, DO
Consulting Fee: AbbVie, Bristol-Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi-Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Ivan O. Rosas, MD
Consulting Fee: Genentech/Roche
Contracted Research: Genentech/Roche

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com